Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avacincaptad pegol - IVERIC bio

Drug Profile

Avacincaptad pegol - IVERIC bio

Alternative Names: Anti-C5 aptamer; ARC-1905; Avacincaptad pegol sodium; Zimura

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer IVERIC bio
  • Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dry age-related macular degeneration
  • Phase II Polypoidal choroidal vasculopathy; Stargardt disease; Wet age-related macular degeneration

Most Recent Events

  • 24 Sep 2021 Biomarkers information updated
  • 26 Jul 2021 IVERIC bio completes enrolment in the phase III GATHER 2 trial for Dry age-related macular degenration in Hungary, Spain, Estonia, Latvia, Czech Republic, The UK, Germany, Poland, Italy, Croatia
  • 21 Jul 2021 IVERIC bio announces intention to launch avacincaptad pegol for Dry age-related macular degeneration
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top